论文部分内容阅读
目的:探讨柴胡疏肝散对肝纤维化的防治作用。方法:70只Wistar大鼠随机分为7组:正常组、病理模型组、秋水仙碱治疗组、柴胡疏肝散低、中、高剂量组、柴胡疏肝散预防组。除正常组外,其余各组均采用猪血清腹腔注射诱发肝纤维化,0.5 m L/只,2次/周,连续10周,5周后即可形成肝纤维化。预防组于造模同时给药(以柴胡疏肝散6.3 g·kg-1),各治疗组于造模第6周给药,持续至第10周。秋水仙碱治疗组剂量0.5 m L·kg-1·d-1,柴胡疏肝散低、中、高剂量组(3.5,6.3,12.6 g·kg-1·d-1)。用全自动分析法测定各组血清肝功能、放射免疫法测定肝纤维化指标,采用酸性水解法检测肝组织羟脯氨酸(hydroxyproline,HYP)含量,并观察病理变化。结果:与模型组比较,柴胡疏肝散中剂量组血清丙氨酸转氨酶(ALT),(156.5±3.2)U·L-1VS(78.4±4.6)U·L-1(P<0.01);天冬氨酸转氨酶(AST),(387.4±12.7)U·L-1VS(232.5±13.5)U·L-1(P<0.01);r-谷氨酰转肽酶(GGT),(128.2±4.0)U·L-1VS(78.5±4.2)U·L-1(P<0.01);碱性磷酸酶(ALP),(152.75±5.01)U·L-1VS(42.51±4.67)U·L-1(P<0.01);透明质酸(HA),(337.2±22.1)VS(140.6±21.2)μg·L-1(P<0.01);PCⅢ(145.31±17.14)μg·L-1VS(85.5±19.7)μg·L-1(P<0.05);Ⅳ型胶原(135.1±22.4)VS(88.37±21.09)(P<0.05);层黏连蛋白(LN),(317.5±21.3)VS(148.4±18.4),(P<0.05)含量均显著下降,肝组织(HYP)(527.2±34.2)VS(346.2±43.1)(P<0.01)含量显著降低。结论:柴胡疏肝散有明显的抗肝纤维化作用。
Objective: To explore the preventive and therapeutic effects of Chaihu Shugan San on hepatic fibrosis. Methods: Seventy Wistar rats were randomly divided into 7 groups: normal group, pathological model group, colchicine treatment group, Chaihu Shugan San low, medium and high dose group, Chaihu Shugan Powder prevention group. Except for the normal group, the other groups were given intraperitoneal injection of pig serum induced liver fibrosis, 0.5 m L / only, 2 times / week for 10 weeks, 5 weeks after the formation of liver fibrosis. The prophylaxis group was given at the same time of modeling (with Chaihu Shugan Powder 6.3 g · kg-1), and the treatment groups were given at the 6th week of modeling until the 10th week. Colchicine treatment group dose 0.5 m L · kg-1 · d-1, Chaihu Shugan San low, medium and high dose group (3.5,6.3,12.6 g · kg-1 · d-1). Serum liver function was measured by automatic analysis method. The indexes of hepatic fibrosis were determined by radioimmunoassay. The content of hydroxyproline (HYP) in liver tissue was detected by acid hydrolysis method and the pathological changes were observed. Results: Compared with the model group, the serum ALT, (156.5 ± 3.2) U · L-1VS (78.4 ± 4.6) U · L-1 (P <0.01) Aspartate aminotransferase (AST), (387.4 ± 12.7) U · L-1VS (232.5 ± 13.5) U · L -1 (P <0.01) (P <0.01); alkaline phosphatase (ALP), (152.75 ± 5.01) U · L-1VS (42.51 ± 4.67) U · L- (P <0.01); hyaluronic acid (HA) was (337.2 ± 22.1) VS (140.6 ± 21.2) μg · L -1 (P <0.01); PCⅢ (145.31 ± 17.14) μg · L -1VS 19.7) μg · L-1 (P <0.05). Collagen type Ⅳ (135.1 ± 22.4) VS (88.37 ± 21.09), P < 18.4) (P <0.05), and the levels of HYP (527.2 ± 34.2) VS (346.2 ± 43.1) (P <0.01) were significantly decreased. Conclusion: Chaihu Shugan San has obvious anti-hepatic fibrosis.